Investors might want to bet on Candel Therapeutics, Inc. (CADL) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and followi ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, su ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestonesNEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Charles Schoch as Chief Financial Officer (CFO). Mr. Schoch, who ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Insights - Candel Therapeutics has appointed Dr. Maha Radhakrishnan to its Board of Directors, effective June 4, 2025, to enhance its strategic capabilities as it moves towards Biologics License Application (BLA) submission and commercial development [1][2][4] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies aimed at treating cancer [5] - The company has two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [5] Product Development - Candel's lead product candidate, CAN-2409, is being developed for intermediate-to-high-risk prostate cancer, with BLA submission anticipated in Q4 2026 [2][4] - Recent successful phase 2a clinical trials of CAN-2409 were completed in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [6] - CAN-2409 has received Fast Track Designation from the FDA for treating PDAC and stage III/IV NSCLC in specific patient populations [6] Leadership Experience - Dr. Radhakrishnan brings over 20 years of experience in product development and commercialization from major biotechnology and pharmaceutical companies [3] - Her previous roles include Senior Vice President and Chief Medical Officer at Biogen and Global Head of Medical at Sanofi [3] Future Outlook - The company aims to leverage Dr. Radhakrishnan's expertise as it prepares for the BLA submission and advances its innovative immunotherapy candidates [2][4]

Candel Therapeutics (CADL) 2025 Conference June 05, 2025 11:40 AM ET Speaker0 Morning, everybody. Welcome to the Jefferies Global Healthcare Conference. My name is Brett Gallagher with the Healthcare Investment Banking team. It's now my pleasure to invite Paul Peter Tock from Candel Therapeutics up to the stage. Speaker1 Thank you very much. A very good morning, everybody. It's great to be here and to present our programs at Candel Therapeutics. We are focused on the development of viral immunotherapies for ...

Shares of Candel Therapeutics, Inc. (CADL) have gained 3.2% over the past four weeks to close the last trading session at $5.45, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21 indicates a potential upside of 285.3%.The average comprises four short-term price targets ranging from a low of $15 to a high of $25, with a standard deviation of $4.90. While the lowest estimate ind ...

Candel Therapeutics (CADL) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational adenovirus immunotherapy candidate, CAN-2409 (aglatimagene besadenovec), for treating newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk of the disease.The RMAT tag was granted based on positive data from a phase III study, which evaluated the safety and efficacy of CAN-2409+prodrug (valacyclovir)+standard of care (SOC) radiation ...